Marksans Pharma Ltd

Marksans Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Marksans Pharma Ltd

₹ 245 3.63%
21 May 2:14 p.m.
marksanspharma.com BSE: 524404 NSE: MARKSANS
About

Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products [1]

Key Points

Product Portfolio
OTC Products: (74% of FY24 revenue)
Include Pain Management, Cough and Cold, Digestive Remedies, Vitamins and Tonics, Skin Treatments, and Allergies.[1]
Prescription (Rx) Products: (26%)[2]
Includes cardiovascular, central nervous system (CNS), anti-allergic, anticancer, and anti-diabetic drugs.

Website BSE NSE
  • Market Cap ₹ 11,114 Cr.
  • Current Price ₹ 245
  • High / Low ₹ 359 / 130
  • Stock P/E 29.2
  • Book Value ₹ 54.4
  • Dividend Yield 0.24 %
  • ROCE 20.1 %
  • ROE 16.8 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has delivered good profit growth of 25.8% CAGR over last 5 years

Cons

  • Promoter holding has decreased over last 3 years: -4.38%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations

Part of BSE Healthcare BSE SmallCap BSE Allcap Nifty Microcap 250 Nifty Total Market

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
418 434 453 480 486 500 531 586 560 591 642 682 708
354 361 372 403 376 398 417 453 450 462 506 543 583
Operating Profit 64 73 80 77 110 102 114 133 110 128 136 139 126
OPM % 15% 17% 18% 16% 23% 20% 21% 23% 20% 22% 21% 20% 18%
15 16 14 18 11 10 19 5 17 15 11 28 17
Interest 5 2 3 2 2 2 2 3 5 3 3 3 3
Depreciation 21 11 14 13 14 14 18 22 21 20 20 21 23
Profit before tax 53 76 78 79 104 97 114 113 100 120 125 143 116
Tax % 44% 21% 23% 21% 21% 27% 26% 26% 23% 26% 22% 27% 22%
30 60 60 62 83 70 84 83 78 89 98 105 91
EPS in Rs 0.69 1.46 1.51 1.57 1.81 1.52 1.84 1.84 1.73 1.96 2.13 2.31 2.00
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
630 797 893 767 913 1,000 1,134 1,376 1,491 1,852 2,177 2,623
512 612 757 722 834 868 942 1,037 1,232 1,513 1,719 2,094
Operating Profit 118 185 136 45 78 132 192 340 259 340 459 529
OPM % 19% 23% 15% 6% 9% 13% 17% 25% 17% 18% 21% 20%
4 3 9 7 8 5 0 7 42 59 50 70
Interest 19 16 10 7 10 10 9 8 8 9 11 12
Depreciation 16 16 28 30 27 23 27 36 45 52 74 83
Profit before tax 86 156 107 15 50 104 157 302 248 338 424 504
Tax % 15% 28% 23% 24% 28% 23% 23% 21% 25% 21% 26% 24%
74 112 83 11 36 80 121 239 187 265 315 383
EPS in Rs 1.87 2.67 1.92 0.22 0.80 1.87 2.95 5.76 4.51 5.88 6.92 8.40
Dividend Payout % 5% 4% 21% 23% 6% 3% 3% 4% 6% 9% 9% 10%
Compounded Sales Growth
10 Years: 13%
5 Years: 18%
3 Years: 21%
TTM: 20%
Compounded Profit Growth
10 Years: 13%
5 Years: 26%
3 Years: 27%
TTM: 21%
Stock Price CAGR
10 Years: 15%
5 Years: 65%
3 Years: 69%
1 Year: 44%
Return on Equity
10 Years: 17%
5 Years: 19%
3 Years: 17%
Last Year: 17%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 39 41 41 41 41 41 41 41 41 45 45 45
Reserves 90 326 401 392 430 502 595 846 1,161 1,700 2,020 2,422
173 101 100 110 118 100 30 34 111 123 244 322
188 207 180 209 142 160 236 307 323 322 372 451
Total Liabilities 490 676 722 752 731 802 902 1,228 1,636 2,190 2,681 3,240
146 166 270 267 279 270 303 309 428 486 776 1,000
CWIP 0 0 0 0 0 0 0 12 3 10 9 9
Investments 0 0 0 0 0 0 0 0 0 1 27 1
344 510 452 484 451 533 599 907 1,205 1,694 1,869 2,230
Total Assets 490 676 722 752 731 802 902 1,228 1,636 2,190 2,681 3,240

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
65 155 31 14 50 27 233 179 99 237 230 207
-4 -33 -123 -21 -39 -13 -60 -45 -84 -259 -141 -49
-29 17 -58 -3 3 -21 -114 -15 80 198 -69 -65
Net Cash Flow 31 138 -150 -10 15 -7 60 118 94 176 21 93

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 98 84 89 118 71 64 78 72 97 82 76 75
Inventory Days 102 107 120 151 152 215 155 248 216 192 217 270
Days Payable 83 88 85 129 54 78 71 103 102 91 94 98
Cash Conversion Cycle 118 103 124 140 169 202 163 217 211 183 199 247
Working Capital Days 48 55 95 130 117 133 94 110 138 133 138 150
ROCE % 37% 44% 23% 4% 10% 18% 25% 38% 23% 22% 21% 20%

Shareholding Pattern

Numbers in percentages

Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
48.25% 48.60% 49.00% 43.85% 43.85% 43.85% 43.85% 43.85% 43.87% 43.87% 43.87% 43.87%
4.04% 4.06% 4.23% 15.11% 14.90% 15.07% 15.55% 15.57% 18.59% 21.31% 21.95% 22.19%
0.94% 0.95% 0.96% 1.46% 3.65% 4.02% 4.76% 5.17% 3.75% 4.10% 4.30% 4.55%
46.77% 46.38% 45.79% 39.57% 37.60% 37.06% 35.81% 35.40% 33.77% 30.70% 29.88% 29.37%
No. of Shareholders 2,21,3592,17,7432,13,1231,98,3821,88,4472,07,9372,37,3772,54,6992,35,5002,48,8452,59,8132,57,273

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls